Physician profile
John Coleman
NPI 1063945475
$2,494.48
in general payments reported to CMS, 2019-2025
22 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.12 · 2020: $307 · 2021: $510 · 2022: $264 · 2023: $516 · 2024: $440 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $603.53 | 2020-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $397.12 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $313.21 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $190.36 | 2020-2024 | Zepbound, Mounjaro |
| Abbvie INC. | $179.56 | 2020-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $141.96 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $123.64 | 2021 | |
| Xeris Pharmaceuticals, INC. | $74.72 | 2023-2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.97 | 2022-2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $67.10 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.17 | 2025 | Caplyta |
| Amgen INC. | $42.47 | 2023-2024 | Repatha, Otezla, Prolia |
| Ovik Health, LLC | $35.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.37 | 2020-2021 | |
| Biogen, INC. | $32.25 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.60 | 2021-2024 | Verquvo |
| Pfizer INC. | $26.56 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.48 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.35 | 2025 | Rexulti |
| Celgene Corporation | $16.09 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.27 | 2023 | |
| Corium, LLC | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.